Pitfalls in Clinical Trials and Future Directions
作者： Philip A. Philip , Lance K. Heilbrun , Judith Abrams
DOI: 10.1007/978-0-387-69252-4_44
关键词:
摘要:
springer.com
sci-hub.st 参考文章(24)
Jeremy MG Taylor, Thomas M Braun, Zhiguo Li, Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design Clinical Trials. ,vol. 3, pp. 335- 348 ,(2006) , 10.1177/1740774506070654
Therese Deramaudt, Anil K. Rustgi, Mutant KRAS in the initiation of pancreatic cancer. Biochimica et Biophysica Acta. ,vol. 1756, pp. 97- 101 ,(2005) , 10.1016/J.BBCAN.2005.08.003
Daniel J. Sargent, Barbara A. Conley, Carmen Allegra, Laurence Collette, Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials Journal of Clinical Oncology. ,vol. 23, pp. 2020- 2027 ,(2005) , 10.1200/JCO.2005.01.112
Toru Furukawa, Makoto Sunamura, Akira Horii, Molecular mechanisms of pancreatic carcinogenesis. Cancer Science. ,vol. 97, pp. 1- 7 ,(2006) , 10.1111/J.1349-7006.2005.00134.X
P.Y Liu, Michael LeBlanc, Manisha Desai, False positive rates of randomized phase II designs. Controlled Clinical Trials. ,vol. 20, pp. 343- 352 ,(1999) , 10.1016/S0197-2456(99)00009-4
Jay P. Overholser, Marie C. Prewett, Andrea T. Hooper, Harlan W. Waksal, Daniel J. Hicklin, Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer. ,vol. 89, pp. 74- 82 ,(2000) , 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K
Girish Mishra, DNA analysis of cells obtained from endoscopic ultrasound-fine needle aspiration in pancreatic adenocarcinoma: Fool's Gold, Pandora's Box, or Holy Grail? The American Journal of Gastroenterology. ,vol. 101, pp. 2501- 2503 ,(2006) , 10.1111/J.1572-0241.2006.00929.X
Fadi Braiteh, Razelle Kurzrock, Uncommon tumors and exceptional therapies: paradox or paradigm? Molecular Cancer Therapeutics. ,vol. 6, pp. 1175- 1179 ,(2007) , 10.1158/1535-7163.MCT-06-0674
Andrew Stone, Catherine Wheeler, Alan Barge, Improving the design of phase II trials of cytostatic anticancer agents Contemporary Clinical Trials. ,vol. 28, pp. 138- 145 ,(2007) , 10.1016/J.CCT.2006.05.009
Gary L. Rosner, Walter Stadler, Mark J. Ratain, Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents Journal of Clinical Oncology. ,vol. 20, pp. 4478- 4484 ,(2002) , 10.1200/JCO.2002.11.126